Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction Article Swipe

PDF

Related Concepts

Empagliflozin Medicine Ejection fraction Myocardial infarction Hazard ratio Internal medicine Cardiology Heart failure Placebo Confidence interval Diabetes mellitus Type 2 diabetes Endocrinology Alternative medicine Pathology

Jacob A. Udell , Mark C. Petrie , W. Schuyler Jones , Stefan D. Anker , Josephine Harrington , Michaela Mattheus , Svenja Seide , Offer Amir , M. Cecilia Bahit , Johann Bauersachs , Antoni Bayés‐Genís , Yundai Chen , Vijay Chopra , Gemma A. Figtree , Junbo Ge , Shaun G. Goodman , Nina Gotcheva , Shinya Goto , Tomasz Gąsior , Waheed Jamal , James L. Januzzi , Myung Ho Jeong , Yu. M. Lopatin , Renato D. Lópes , Béla Merkely , Monica Martinez-Traba , Puja B. Parikh , Alexander Parkhomenko , Piotr Ponikowski , Xavier Rosselló , Morten Schou , Dragan Šimić , Philippe Gabríel Steg , Joanna Szachniewicz , Peter van der Meer , Dragoş Vinereanu , Shelley Zieroth , Martina Brueckmann , Mikhail Sumin , Deepak L. Bhatt , Adrian F. Hernandez , Javed Butler ·

YOU? · · 2024 · Open Access · · DOI: https://doi.org/10.1016/j.jacc.2024.03.405 · OA: W4394014919

In patients with AMI, the severity of left ventricular dysfunction and the presence of congestion was associated with worse outcomes. Empagliflozin reduced first and total HF hospitalizations across the range of LVEF with and without congestion. (Trial to Evaluate the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction [EMPACT-MI]; NCT04509674).